R. Dent

539 total citations
12 papers, 337 citations indexed

About

R. Dent is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, R. Dent has authored 12 papers receiving a total of 337 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 4 papers in Cancer Research. Recurrent topics in R. Dent's work include Breast Cancer Treatment Studies (4 papers), Cancer Treatment and Pharmacology (4 papers) and Cancer Immunotherapy and Biomarkers (3 papers). R. Dent is often cited by papers focused on Breast Cancer Treatment Studies (4 papers), Cancer Treatment and Pharmacology (4 papers) and Cancer Immunotherapy and Biomarkers (3 papers). R. Dent collaborates with scholars based in Spain, Canada and United States. R. Dent's co-authors include Cezary Cybulski, Jerzy Jakubowicz, Tomasz Byrski, J. Gronwald, Jan Lubiński, Marek Jasiówka, S A Narod, Rafał Wiśniowski, Elżbieta Marczyk and Dariusz Godlewski and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

R. Dent

12 papers receiving 329 citations

Peers

R. Dent

ONCOL

GENET

PRM

Mallika Dhawan United States

Diana Nariţa Romania

Simone Millinger Austria

Orsolya Rusz Hungary

Ann Christina Eriksen Denmark

Dane Cheasley Australia

Julie Tisserand France

Jianjun Xiao China

Jolijn W. Groeneweg Netherlands

Elena Goldin Italy

Mallika Dhawan United States

R. Dent

192 ×0.8

ONCOL

79 ×0.5

41 ×0.4

GENET

98 ×1.1

102 ×1.5

PRM

Citations per year, relative to R. Dent R. Dent (= 1×) peers Mallika Dhawan

Countries citing papers authored by R. Dent

Since Specialization

Citations

This map shows the geographic impact of R. Dent's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Dent with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Dent more than expected).

Fields of papers citing papers by R. Dent

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Dent. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Dent. The network helps show where R. Dent may publish in the future.

Co-authorship network of co-authors of R. Dent

This figure shows the co-authorship network connecting the top 25 collaborators of R. Dent. A scholar is included among the top collaborators of R. Dent based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Dent. R. Dent is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Dent, R., Zhi-Ming Shao, David W. Cescon, et al.. (2025). LBA21 First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Primary results from the randomised, phase III TROPION-Breast02 trial. Annals of Oncology. 36. S1566–S1567. 1 indexed citations

Dent, R., Sherko Kümmel, Jing Zhao, et al.. (2024). LBA4 Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: Overall survival results from the phase III KEYNOTE-522 study. Annals of Oncology. 35. S1204–S1205. 5 indexed citations

Dent, R., Fabrice André, Anthony Gonçalvès, et al.. (2024). 180O IMpassion132 double-blind randomised phase III trial of chemotherapy (CT) ± atezolizumab (atezo) for early-relapsing unresectable locally advanced or metastatic triple-negative breast cancer (aTNBC). ESMO Open. 9. 103202–103202. 3 indexed citations

Cortés, Javier, Oleg Lipatov, S. Im, et al.. (2019). KEYNOTE-119: Phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC). Annals of Oncology. 30. v859–v860. 95 indexed citations

Ng, T.Y., Yan Gan, Gilbert Fan, et al.. (2015). 1543 Trajectory of self-perceived cognitive impairment: A 15-month prospective, longitudinal study in Asian early-stage breast cancer (ESBC) patients. European Journal of Cancer. 51. S218–S219. 1 indexed citations

Byrski, Tomasz, Tomasz Huzarski, R. Dent, et al.. (2014). Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Research and Treatment. 147(2). 401–405. 177 indexed citations

Dawood, Shaheenah, Xiudong Lei, R. Dent, et al.. (2014). Survival of women with inflammatory breast cancer: a large population-based study. Annals of Oncology. 25(6). 1143–1151. 46 indexed citations

Villarreal‐Garza, Cynthia, et al.. (2011). Platinum-based chemotherapy in triple-negative breast cancer.. Journal of Clinical Oncology. 29(15_suppl). 1090–1090. 5 indexed citations

Hilton, John, Lisa Vandermeer, Sean Hopkins, et al.. (2011). A multicenter study assessing 12-weekly intravenous bisphosphonate therapy in women with low-risk bone metastases from breast cancer: The TRIUMPH trial.. Journal of Clinical Oncology. 29(15_suppl). TPS242–TPS242. 1 indexed citations

10.

Draanen, Jenna van, R. Dent, Mark Pasetka, et al.. (2010). Abstract P3-15-05: Muscle and Joint Symptoms in Breast Cancer Patients Receiving Taxane-Based Chemotherapy. Cancer Research. 70(24_Supplement). P3–15. 1 indexed citations

11.

Dent, R., K. Pritchard, Wahid T. Hanna, et al.. (2007). P46 Patterns of recurrence and prognosis in women with basal-like breast cancer. The Breast. 16. S25–S25. 1 indexed citations

12.

Dent, R., Barbara Fitzgerald, L. Lickley, et al.. (2005). Do clinical trials of neoadjuvant chemotherapy for locally advanced breast cancer (LABC) overestimate the actual response rates observed in clinical practice?. Journal of Clinical Oncology. 23(16_suppl). 890–890. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact